Business in the Burbs

Acorda has deal with Danish drugmaker

April

Acorda Therapeutics Inc. of Hawthorne said a Danish drug company will manufacture a key molecule in a substance that Acorda is using in toxicology studies and early phase clinical trials.
Acorda said the company, CMC ICOS Biologics of Copenhagen, will produce the molecule, GGF2, for Acordaâ€™s neuregulin program. Terms of the deal were not announced. Neuregulins have the potential to be helpful in treatments for multiple sclerosis and stroke, Acorda said.

This entry was posted on Wednesday, April 9th, 2008 at 12:44 pm by Jerry Gleeson. You can follow any responses to this entry through the RSS 2.0 feed.
Category: Corporate doings, Health care, Research

Print | Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.